Voyager Therapeutics is shifting towards a new technology to deliver gene therapy and away from a planned HD clinical trial. But this could lead to less invasive drugs in the long run, and many other companies are working on HD gene therapies.
Researchers design a virus to more effectively deliver gene-silencing drugs throughout the brain.
New research reveals blood vessel changes that could contribute to problem in HD
Roche's 'brain shuttle' sneaks drugs past the blood-brain barrier. Could it work for HD gene silencing drugs?
Damage to cells caused by oxidative stress is part of HD - could a new targeted drug help reduce this problem?
Positive results from tests of a new 'KMO inhibiting' drug in Huntington's disease mice